Method of treatment and pronostic of acute myeloid leukemia

The present invention relates to the treatment of AML. The inventors previously discovered a new epigenetic biomarker in a cohort of CN-AML patients; this consists in a strong enrichment in the H3K27me3 histone mark located on a 70 Kb part of the major histone cluster 1 (HIST1) that separates patients into two distinguishable groups defined as H3K27me3HIST1low and H3K27me3HIST1high. Patients harboring the H3K27me3 HIST1 epigenetic mark had a better event free survival. This first observation suggests that H3K27me3HIST1high patients may develop a less aggressive disease. Molecular characterisation of H3K27me3HIST1high patients showed that the linker histone H1d, but not the other histone H1 subtypes, was down-regulated in the H3K27me3 HIST1high group of patients. H1d knockdown primed ATRA differentiation, as assessed on CD11b/CD11c markers, morphological and gene expression analyses. These results suggested that targeting H1d could help to reverse the adverse immature phenotype of the H3K27me3 HIST1low group into the more favourable one of the H3K27me3 HIST1high group of patients and thus could be a good target in AML. Thus the invention relates to an H1d inhibitor for use in the treatment of acute myeloid leukemia (AML) in a patient in need thereof.

Keywords: Epigenetic inhibitor, Companion diagnostic
Patent Application number: EP19 195 629.1
Clin Epigenetics. 2019 Oct 12;11(1):141. doi: 10.1186/s13148-019-0738-6.



Business Developper
Pierre MAZOT
Pierre MAZOT
Business Developer
Patent filling date: 2019-09-05

You might also be interested in